2025-08-21 - Analysis Report
Okay, here's the report on TG Therapeutics Inc (TGTX), incorporating your instructions and data:

## TG Therapeutics Inc (TGTX) Stock Analysis Report

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 14.04%
*   **VOO Cumulative Return:** 37.28%
*   **Absolute Deviation:** -52.2
*   **Relative Deviation:** 11.4
*   **Analysis:** TGTX has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative deviation of 11.4 suggests that TGTX's performance is closer to the lower end of its historical range compared to the benchmark.

### Alpha, Beta Analysis

| Year       | CAGR    | MDD      | Alpha  | Beta  | Cap(B) |
|------------|---------|----------|--------|-------|--------|
| 2015-2017  | 0.0%    | 0.0%     | 0.0%   | 1.0   | 1.3    |
| 2016-2018  | 0.0%    | 0.0%     | 0.0%   | 1.0   | 0.7    |
| 2017-2019  | 0.0%    | 0.0%     | 0.0%   | 1.0   | 1.8    |
| 2018-2020  | 0.0%    | 0.0%     | 0.0%   | 1.0   | 8.2    |
| 2019-2021  | 4.0%    | 0.0%     | 3.0%   | -1.3  | 3.0    |
| 2020-2022  | -45.0%  | 70.2%    | -34.0% | -0.2  | 1.9    |
| 2021-2023  | -6.0%   | 70.2%    | -16.0% | -0.1  | 2.7    |
| 2022-2024  | 67.0%   | 73.0%    | 37.0%  | 0.0   | 4.8    |
| 2023-2025  | 49.0%   | 73.0%    | 5.0%   | 0.0   | 4.5    |

**Analysis:**

*   **CAGR & MDD:** The table shows a wide range of annual growth rates, with significant volatility indicated by high Maximum Drawdown (MDD) values in certain periods (e.g., 2020-2022).
*   **Alpha:**  Alpha is positive in some periods (e.g., 2019-2021, 2022-2024) indicating outperformance relative to the benchmark, but is negative in others, suggesting underperformance.
*   **Beta:** Beta fluctuates, with negative values indicating an inverse correlation with the market during those periods (e.g., 2019-2021). Periods with Beta near 0 suggest the stock's price is relatively independent of the broader market.
*   **Cap(B):** The market capitalization fluctuates over the periods.

### 2. Recent Price Action

*   **Current Price:** \$28.31
*   **Previous Close:** \$27.92
*   **Change:** 1.4%
*   **5-day Moving Average:** \$27.96
*   **20-day Moving Average:** \$30.61
*   **60-day Moving Average:** \$34.91

**Analysis:** The stock is trading above its 5-day moving average but below its 20-day and 60-day moving averages. This suggests a short-term upward trend, but potentially still within a longer-term downtrend. The 1.4% price increase from the previous close reflects some positive momentum.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.3316 (Low Risk)
*   **RSI:** 20.80 (Oversold)
*   **PPO:** -0.1659
*   **Hybrid Signal:** cash_66%_Sell 5.6% of holdings (89 shares - Caution - MRI:0.34)
*   **20-day Relative Deviation Change:** -0.7 (Short-term Decline)
*   **Expected Return:** -367.5%

**Analysis:**

*   The RSI indicates that the stock is currently oversold, which could suggest a potential for a price rebound.
*   The negative PPO value reinforces the downtrend indication.
*   MRI indicates Low Risk.
*   The hybrid signal suggests a cautious approach, recommending increasing cash holdings.
*   The negative expected return suggests significant underperformance relative to the S&P 500 if held for a long-term investment.

### 4. Recent News & Significant Events

*   **[2025-08-20]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-19]:** Analyst discussions on recent performance and outlook.
*   **[2025-08-21]:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-08-18]:** Market experts highlight risks and opportunities, advising monitoring of news and announcements.

**Analysis:** Recent news suggests the stock is experiencing volatility and is subject to market speculation and analyst scrutiny.  Investors should closely monitor upcoming announcements and news.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-08-08 | 0.19 | \$0.14 B     |
| 2025-05-09 | 0.03 | \$0.12 B     |
| 2024-11-07 | 0.03 | \$0.08 B     |
| 2024-08-09 | 0.05 | \$0.07 B     |
| 2025-08-08 | 0.05 | \$0.07 B     |

**Analysis:** The most recent EPS is \$0.19, and revenue is \$0.14 billion. EPS appears to be trending upward in the latest report.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | \$0.14B   | 86.58%        |
| 2025-03-31 | \$0.12B   | 87.14%        |
| 2024-12-31 | \$0.11B   | 85.77%        |
| 2024-09-30 | \$0.08B   | 88.86%        |
| 2024-06-30 | \$0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-06-30 | \$0.28B   | 10.20%  |
| 2025-03-31 | \$0.24B   | 2.13%   |
| 2024-12-31 | \$0.22B   | 10.49%  |
| 2024-09-30 | \$0.19B   | 2.02%   |
| 2024-06-30 | \$0.18B   | 3.87%   |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the past five quarters.
*   **Profit Margin:** The profit margin remains high, consistently above 85%.
*   **Equity:** Equity has grown over the period.
*   **ROE:** ROE fluctuates, with higher values in the later quarters.

### 7. Overall Analysis and Recommendation

TG Therapeutics Inc. (TGTX) exhibits a mixed performance profile. While recent earnings show positive signs, the stock has significantly underperformed the S&P 500. Technical indicators suggest it is currently oversold, which may lead to a short-term rebound. However, the negative expected return and recent news indicating volatility warrant a cautious approach. The hybrid signal reflects this caution, recommending increasing cash holdings. The increase in revenue and high profit margins are positive signs, but investors should closely monitor news and announcements related to the company and the broader market.

**Recommendation:** Given the current data, a **Neutral to Cautious** stance is warranted. Investors should closely monitor future developments and consider the high level of volatility before making any investment decisions.
